Brief: Oncotelic Awarded Barda Funding For Development Of Ot-101 For Long Covid
12/10/2022 12:12
Oct 12 (Reuters) - Oncotelic Therapeutics Inc OTLC.PK :
* ONCOTELIC AWARDED BARDA FUNDING FOR DEVELOPMENT OF OT-101
FOR
LONG COVID
Source text for Eikon: ID:nGNX2LsKln
Further company coverage: OTLC.PK
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas